FibroGen Company Profile (NASDAQ:FGEN)

About FibroGen

FibroGen logoFibroGen, Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200. FG-4592 is an oral small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylases (HIF-PHs), which acts by stimulating the body's natural pathway of erythropoiesis or red blood cell production. FG-4592 is in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD). FG-3019 is a monoclonal antibody, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, Duchenne muscular dystrophy (DMD) and liver fibrosis. FG-6874 is in Phase I clinical trials, and FG-5200 is a corneal implant medical device, which is in preclinical studies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: FGEN
  • CUSIP:
Key Metrics:
  • Previous Close: $23.80
  • 50 Day Moving Average: $23.83
  • 200 Day Moving Average: $20.77
  • 52-Week Range: $14.50 - $25.70
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -14.69
  • P/E Growth: 0.00
  • Market Cap: $1.50B
  • Outstanding Shares: 63,160,000
  • Beta: 1.75
  • Net Margins: -45.93%
  • Return on Equity: -40.38%
  • Return on Assets: -16.66%
  • Debt-to-Equity Ratio: 0.49%
  • Current Ratio: 4.11%
  • Quick Ratio: 4.11%
Additional Links:
Companies Related to FibroGen:

Analyst Ratings

Consensus Ratings for FibroGen (NASDAQ:FGEN) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $38.25 (60.71% upside)

Analysts' Ratings History for FibroGen (NASDAQ:FGEN)
DateFirmActionRatingPrice TargetDetails
1/18/2017RBC Capital MarketsReiterated RatingBuyView Rating Details
1/18/2017Stifel NicolausReiterated RatingPositive$33.00View Rating Details
11/9/2016Leerink SwannReiterated RatingBuy$52.00View Rating Details
8/9/2016Credit Suisse GroupReiterated RatingBuy$37.00View Rating Details
2/22/2016Goldman Sachs Group, Inc. (The)Lower Price Target$34.00 -> $31.00View Rating Details
12/4/2015Citigroup Inc.Initiated CoverageBuy$40.00View Rating Details
9/23/2015Lake Street CapitalInitiated CoverageHold$25.00View Rating Details
(Data available from 2/22/2015 forward)


Earnings History for FibroGen (NASDAQ:FGEN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2016Q3($0.59)($0.38)$24.30 million$30.10 millionViewListenView Earnings Details
5/9/2016Q116($0.56)($0.45)$17.74 millionViewListenView Earnings Details
2/29/2016Q4($0.54)($0.85)ViewListenView Earnings Details
11/12/2015Q3($0.61)($0.74)ViewListenView Earnings Details
8/13/2015Q215$0.73$0.83$111.75 million$120.55 millionViewListenView Earnings Details
5/12/2015Q115($0.52)($0.78)$34.00 million$16.30 millionViewN/AView Earnings Details
3/26/2015Q414($0.90)($0.82)$16.49 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for FibroGen (NASDAQ:FGEN)
Current Year EPS Consensus Estimate: $-1.04 EPS
Next Year EPS Consensus Estimate: $-1.62 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($0.84)($0.59)($0.70)
Q2 20164$0.15$0.43$0.30
Q3 20163($0.76)($0.52)($0.64)
Q4 20163($0.74)($0.69)($0.71)
Q1 20171($0.67)($0.67)($0.67)
Q2 20171($0.67)($0.67)($0.67)
Q3 20171($0.68)($0.68)($0.68)
Q4 20171($0.75)($0.75)($0.75)
(Data provided by Zacks Investment Research)


Dividend History for FibroGen (NASDAQ:FGEN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for FibroGen (NASDAQ:FGEN)
Insider Ownership Percentage: 14.90%
Institutional Ownership Percentage: 47.74%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/16/2017Kalevi KurkijarviDirectorSell2,000$24.45$48,900.00View SEC Filing  
2/14/2017Thomas B NeffCEOSell38,636$23.94$924,945.84View SEC Filing  
2/13/2017Thomas B NeffCEOSell18,900$23.97$453,033.00View SEC Filing  
2/9/2017Thomas B NeffCEOSell37,798$23.46$886,741.08View SEC Filing  
1/27/2017Thomas B NeffCEOSell37,798$23.29$880,315.42View SEC Filing  
1/19/2017Kalevi KurkijarviDirectorSell2,000$24.90$49,800.00View SEC Filing  
1/12/2017Thomas B NeffCEOSell37,798$23.85$901,482.30View SEC Filing  
1/11/2017Pat CotroneoVPSell6,500$24.00$156,000.00View SEC Filing  
1/10/2017K Peony YuInsiderSell5,000$23.56$117,800.00View SEC Filing  
12/28/2016Thomas B NeffCEOSell37,798$20.74$783,930.52View SEC Filing  
12/16/2016Rory B RiggsDirectorSell20,000$20.87$417,400.00View SEC Filing  
12/13/2016Thomas B NeffCEOSell37,798$21.24$802,829.52View SEC Filing  
12/12/2016Pat CotroneoVPSell2,344$22.05$51,685.20View SEC Filing  
12/12/2016Thomas B NeffCEOSell18,899$21.48$405,950.52View SEC Filing  
11/29/2016Thomas B NeffCEOSell37,798$22.80$861,794.40View SEC Filing  
11/28/2016Thomas B NeffCEOSell18,899$22.74$429,763.26View SEC Filing  
11/18/2016Thomas F Kearns JrDirectorSell18,000$22.40$403,200.00View SEC Filing  
11/17/2016Thomas B NeffCEOSell37,798$22.29$842,517.42View SEC Filing  
11/1/2016Thomas B NeffCEOSell37,798$16.76$633,494.48View SEC Filing  
10/19/2016Thomas B NeffCEOSell37,798$17.75$670,914.50View SEC Filing  
10/18/2016Thomas B NeffCEOSell18,899$17.94$339,048.06View SEC Filing  
10/4/2016Thomas B NeffCEOSell18,899$20.67$390,642.33View SEC Filing  
10/3/2016Thomas B NeffCEOSell18,899$20.55$388,374.45View SEC Filing  
9/21/2016Thomas B NeffCEOSell37,798$21.66$818,704.68View SEC Filing  
9/14/2016K Peony YuInsiderSell2,345$18.66$43,757.70View SEC Filing  
9/12/2016Pat CotroneoVPSell2,345$18.22$42,725.90View SEC Filing  
9/9/2016Thomas B NeffCEOSell37,798$18.99$717,784.02View SEC Filing  
8/26/2016Thomas B NeffCEOSell37,798$17.80$672,804.40View SEC Filing  
7/27/2016Thomas B NeffCEOSell37,798$18.38$694,727.24View SEC Filing  
7/13/2016Thomas B NeffCEOSell27,000$17.50$472,500.00View SEC Filing  
6/29/2016Thomas B NeffCEOSell27,000$16.02$432,540.00View SEC Filing  
6/15/2016Pat CotroneoCFOSell1,796$16.49$29,616.04View SEC Filing  
6/15/2016Thomas B NeffCEOSell27,000$16.48$444,960.00View SEC Filing  
6/10/2016K Peony YuInsiderSell2,344$17.96$42,098.24View SEC Filing  
6/3/2016Thomas B NeffCEOSell27,000$18.99$512,730.00View SEC Filing  
5/20/2016Thomas B NeffCEOSell27,000$17.68$477,360.00View SEC Filing  
5/16/2016Pat CotroneoCFOSell6,107$17.60$107,483.20View SEC Filing  
5/3/2016Thomas B NeffCEOSell27,000$17.78$480,060.00View SEC Filing  
4/20/2016Thomas B NeffCEOSell27,000$19.98$539,460.00View SEC Filing  
4/19/2016Thomas B NeffCEOSell13,500$20.21$272,835.00View SEC Filing  
4/5/2016Thomas B NeffCEOSell27,000$21.11$569,970.00View SEC Filing  
4/1/2016Frank H Md ValoneInsiderSell10,750$21.11$226,932.50View SEC Filing  
3/22/2016Thomas B NeffCEOSell27,000$18.74$505,980.00View SEC Filing  
3/8/2016Thomas B NeffCEOSell27,000$19.62$529,740.00View SEC Filing  
3/1/2016Frank H Md ValoneInsiderSell10,750$16.84$181,030.00View SEC Filing  
2/23/2016Thomas B NeffCEOSell27,000$19.11$515,970.00View SEC Filing  
2/22/2016Thomas B NeffCEOSell13,500$19.81$267,435.00View SEC Filing  
2/16/2016Frank H. Md ValoneinsiderSell10,750$18.41$197,907.50View SEC Filing  
2/10/2016Thomas B. NeffCEOSell27,000$15.31$413,370.00View SEC Filing  
1/29/2016Thomas B. NeffCEOSell27,000$19.41$524,070.00View SEC Filing  
1/21/2016Thomas F Kearns JrDirectorSell1,572$22.08$34,709.76View SEC Filing  
1/14/2016Thomas B. NeffCEOSell27,000$23.69$639,630.00View SEC Filing  
12/24/2015Thomas F. Kearns, Jr.DirectorSell7,800$30.88$240,864.00View SEC Filing  
12/23/2015Thomas B. NeffCEOSell27,000$30.10$812,700.00View SEC Filing  
12/11/2015Thomas B. NeffCEOSell27,000$29.59$798,930.00View SEC Filing  
12/10/2015K Peony YuVPSell1,093$28.96$31,653.28View SEC Filing  
12/8/2015Miguel MaderoDirectorSell40,386$30.49$1,231,369.14View SEC Filing  
11/30/2015K Peony YuVPSell5,000$30.00$150,000.00View SEC Filing  
11/25/2015Pat CotroneoCFOSell5,000$30.00$150,000.00View SEC Filing  
11/24/2015Thomas B. NeffCEOSell13,500$28.98$391,230.00View SEC Filing  
11/24/2015Thomas F. Kearns, Jr.DirectorSell3,900$29.00$113,100.00View SEC Filing  
11/23/2015Thomas B. NeffCEOSell13,500$27.99$377,865.00View SEC Filing  
11/23/2015Thomas F. Kearns, Jr.DirectorSell3,900$28.02$109,278.00View SEC Filing  
11/17/2015K Peony YuVPSell5,000$28.00$140,000.00View SEC Filing  
11/10/2015K Peony YuVPSell5,000$25.62$128,100.00View SEC Filing  
11/9/2015K Peony YuVPSell2,500$25.00$62,500.00View SEC Filing  
11/2/2015Frank H. Md ValoneinsiderSell10,000$23.18$231,800.00View SEC Filing  
10/30/2015Thomas B. NeffCEOSell27,000$24.06$649,620.00View SEC Filing  
10/21/2015Thomas F. Kearns, Jr.DirectorSell7,800$23.83$185,874.00View SEC Filing  
10/19/2015Frank H. Md ValoneinsiderSell10,000$23.00$230,000.00View SEC Filing  
10/19/2015K Peony YuVPSell5,000$24.00$120,000.00View SEC Filing  
10/16/2015K Peony YuVPSell5,000$21.46$107,300.00View SEC Filing  
10/16/2015Thomas B. NeffCEOSell27,000$21.86$590,220.00View SEC Filing  
10/2/2015Thomas B. NeffCEOSell27,000$21.59$582,930.00View SEC Filing  
10/1/2015Frank H. Md ValoneinsiderSell10,000$21.38$213,800.00View SEC Filing  
9/18/2015Thomas B. NeffCEOSell27,000$29.10$785,700.00View SEC Filing  
9/15/2015Pat CotroneoCFOSell1,093$27.95$30,549.35View SEC Filing  
9/14/2015Rory B. RiggsDirectorSell50,000$27.61$1,380,500.00View SEC Filing  
9/11/2015Miguel MaderoDirectorSell20,600$27.66$569,796.00View SEC Filing  
9/10/2015K Peony YuVPSell1,093$27.84$30,429.12View SEC Filing  
9/10/2015Pat CotroneoCFOSell7,500$27.33$204,975.00View SEC Filing  
9/4/2015Thomas B. NeffCEOSell13,500$22.88$308,880.00View SEC Filing  
9/3/2015Thomas B. NeffCEOSell13,500$22.92$309,420.00View SEC Filing  
9/1/2015Frank H. Md ValoneinsiderSell10,000$23.58$235,800.00View SEC Filing  
7/23/2015Thomas B NeffCEOSell27,000$24.71$667,170.00View SEC Filing  
7/20/2015Frank H Md ValoneInsiderSell1,000$23.70$23,700.00View SEC Filing  
7/20/2015Pat CotroneoCFOSell7,881$23.47$184,967.07View SEC Filing  
7/9/2015Thomas B NeffCEOSell27,000$22.11$596,970.00View SEC Filing  
7/6/2015K Peony YuVPSell5,381$22.69$122,094.89View SEC Filing  
6/25/2015Thomas B NeffCEOSell27,000$23.57$636,390.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for FibroGen (NASDAQ:FGEN)
DateHeadline logoHow These Biotech Stocks are Faring? -- Neuralstem, Catalyst Biosciences, Trevena, and FibroGen (NASDAQ:FGEN) - February 22 at 9:46 AM
News IconFibroGen Inc FGEN Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:FGEN) - February 19 at 10:48 AM
News IconFibroGen, Inc (NASDAQ:FGEN) Quarterly EPS At $-0.6533 - Stock Observer (NASDAQ:FGEN) - February 17 at 3:45 PM logoFIBROGEN INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:FGEN) - February 16 at 5:08 PM
News IconFibroGen, Inc (NASDAQ:FGEN) Daily Sentiment Score At 0.39 - Stock Observer (NASDAQ:FGEN) - February 11 at 5:16 PM logoFibroGen, Inc (NASDAQ:FGEN) Is Expected To Post EPS Of $-0.6533 - (NASDAQ:FGEN) - February 7 at 11:28 PM
News IconShares in Review: Watching the Levels for FibroGen, Inc. (NASDAQ:FGEN) - Baxter Review (NASDAQ:FGEN) - February 7 at 6:27 PM
News IconFibroGen, Inc (NASDAQ:FGEN) Daily Sentiment Score At 0.261 - Stock Observer (NASDAQ:FGEN) - February 5 at 10:03 PM logoHigher pamrevlumab exposure associated with improved survival (NASDAQ:FGEN) - February 3 at 5:37 PM logoFibroGen Announces Publication of Pamrevlumab (FG-3019) Clinical Data in Pancreatic Cancer Showing Safety and Improved Survival Outcomes in Combination with Chemotherapy (NASDAQ:FGEN) - February 3 at 5:37 PM
News IconQuarterly EPS Of FibroGen, Inc (NASDAQ:FGEN) Set At $-0.6533 - Stock Observer (NASDAQ:FGEN) - February 3 at 3:45 AM logoFibroGen : FibroGens Roxadustat (FG-4592) Meets Primary Endpoints in Two Phase 3 Anemia Studies in China (NASDAQ:FGEN) - January 31 at 10:53 PM
News IconLooking Ahead for FibroGen, Inc (NASDAQ:FGEN); Are These Shares Ready to Go Higher? - Aiken Advocate (NASDAQ:FGEN) - January 31 at 5:52 PM logoFibroGen, Inc (NASDAQ:FGEN) EPS Projection At $-0.6533 - (NASDAQ:FGEN) - January 31 at 5:52 PM logoFibroGen, Inc. breached its 50 day moving average in a Bearish Manner : FGEN-US : January 31, 2017 (NASDAQ:FGEN) - January 31 at 5:52 PM logoAEZS Inches Closer To D-Day, EYEG Catches Investors' Eyes, MCRB On Watch (NASDAQ:FGEN) - January 31 at 3:57 AM logoFibroGen's Roxadustat Meets Primary Goals In Two Phase 3 Anemia Studies In China (NASDAQ:FGEN) - January 30 at 12:04 PM logoFibroGen's Roxadustat (FG-4592) Meets Primary Endpoints in Two Phase 3 Anemia Studies in China (NASDAQ:FGEN) - January 30 at 12:04 PM logoFibroGen (FGEN) Roxadustat Meets Primary Endpoints in Phase 3 Trials (NASDAQ:FGEN) - January 30 at 12:04 PM logoFibroGen’s Roxadustat (FG-4592) Meets Primary Endpoints in Two Phase 3 Anemia Studies in China (NASDAQ:FGEN) - January 30 at 12:04 PM logo7:01 am FibroGen announces Roxadustat meets primary endpoints in two phase 3 anemia studies of roxadustat in China (NASDAQ:FGEN) - January 30 at 12:04 PM logoAurinia Pharmaceuticals (AUPH) Jumps: Stock Rises 5.6% (NASDAQ:FGEN) - January 30 at 12:04 PM
News IconFibroGen, Inc (NASDAQ:FGEN) Daily Sentiment Score At 0.457 ... - Stock Observer (NASDAQ:FGEN) - January 29 at 5:16 PM
News IconF-Score in Focus for FibroGen, Inc. (NASDAQ:FGEN) - The Tribune (NASDAQ:FGEN) - January 29 at 5:16 PM
News IconRSI, CCI, and ADX Levels in View for Fibrogen Inc (FGEN) - Market Point (NASDAQ:FGEN) - January 26 at 6:37 PM
News IconEarnings in Full Force, Analysts Take Aim at FibroGen, Inc (NASDAQ:FGEN) - Wall Street Beacon (NASDAQ:FGEN) - January 26 at 6:37 PM logoFibroGen Set Up For A Big Year (NASDAQ:FGEN) - January 25 at 6:38 PM
News IconEarnings Analysis & Update for FibroGen, Inc (NASDAQ:FGEN)? - Aiken Advocate (NASDAQ:FGEN) - January 25 at 3:55 AM
News IconInteresting FGEN Put And Call Options For September 15th (NASDAQ:FGEN) - January 24 at 5:52 PM logoFibroGen (FGEN) Shares March Higher, Can It Continue? (NASDAQ:FGEN) - January 23 at 10:46 AM
News IconWorthy Start of the Year for Biotech Companies (NASDAQ:FGEN) - January 20 at 6:29 PM logoPamrevlumab Pancreatic Cancer Clinical Data Presented at ASCO 2017 Gastrointestinal Cancers Symposium (NASDAQ:FGEN) - January 20 at 6:29 PM logo5:08 pm FibroGen reports updated results from ongoing clinical study of pamrevlumab (FG-3019) with 'promising' safety and efficacy observed (NASDAQ:FGEN) - January 20 at 6:29 PM logoWarriors arena foe's options after court decision? Play, pass or quit (NASDAQ:FGEN) - January 18 at 5:37 PM logoFibroGen : Here Are Two Market Moving Biotech Catalysts To Watch This Week (NASDAQ:FGEN) - January 16 at 5:17 PM
News IconWill The Needle Move For FibroGen, Inc (NASDAQ:FGEN) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:FGEN) - January 12 at 9:07 PM
News IconFirst Week of February 17th Options Trading For FibroGen (FGEN) (NASDAQ:FGEN) - January 12 at 4:05 PM logoFibroGen: An Anemic Company With A Cloudy 2017 (NASDAQ:FGEN) - January 4 at 6:20 PM
News IconDaily Sentiment Score Of FibroGen, Inc (NASDAQ:FGEN) At 0 - Stock Observer (NASDAQ:FGEN) - December 31 at 5:12 PM logoInsider Trading Activity FibroGen, Inc (NASDAQ:FGEN) – CEO Sold 37798 shares of Stock - Market Exclusive (NASDAQ:FGEN) - December 31 at 5:12 PM logoInsider Trading Activity FibroGen, Inc (NASDAQ:FGEN) – CEO Sold 37,798 shares of Stock (NASDAQ:FGEN) - December 30 at 5:36 PM logoWill 2017 Be a Make or Break Year for FibroGen? (NASDAQ:FGEN) - December 30 at 5:36 PM
News IconQuarterly EPS Of FibroGen, Inc (NASDAQ:FGEN) At $-0.6533 - Stock Observer (NASDAQ:FGEN) - December 30 at 3:23 AM
News IconBearish Target Of FibroGen, Inc (NASDAQ:FGEN) At $52 - Stock Observer (NASDAQ:FGEN) - December 27 at 5:21 PM logoFibroGen, Inc. – Value Analysis (NASDAQ:FGEN) : December 23, 2016 (NASDAQ:FGEN) - December 23 at 5:25 PM logoCommit To Purchase FibroGen At $10, Earn 10.2% Annualized Using Options (NASDAQ:FGEN) - December 22 at 5:26 PM logoWhy Akebia Therapeutics Inc Stock Zoomed Higher Today (NASDAQ:FGEN) - December 22 at 5:26 PM logoFibroGen, Inc. breached its 50 day moving average in a Bearish Manner : FGEN-US : December 22, 2016 (NASDAQ:FGEN) - December 22 at 5:26 PM
News IconChart Indicators in Focus for Fibrogen Inc (FGEN) - StockTalk Daily (NASDAQ:FGEN) - December 21 at 6:02 PM logoAkebia Therapeutics Inc (NASDAQ:AKBA): Here’s What You Need To Know (NASDAQ:FGEN) - December 21 at 10:57 AM


What is FibroGen's stock symbol?

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

Where is FibroGen's stock going? Where will FibroGen's stock price be in 2017?

4 equities research analysts have issued 12-month target prices for FibroGen's stock. Their forecasts range from $31.00 to $52.00. On average, they anticipate FibroGen's stock price to reach $38.25 in the next twelve months.

When will FibroGen announce their earnings?

FibroGen is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.

Who owns FibroGen stock?

FibroGen's stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (2.43%), State Street Corp (2.16%), Janus Capital Management LLC (2.14%), EcoR1 Capital LLC (1.09%), Pinnacle Associates Ltd. (1.08%) and Renaissance Technologies LLC (0.53%). Company insiders that own FibroGen stock include Frank H Md Valone, K Peony Yu, Kalevi Kurkijarvi, Miguel Madero, Pat Cotroneo, Rory B Riggs, Thomas B Neff, Thomas F Kearns Jr and Thomas F Kearns, Jr.

Who sold FibroGen stock? Who is selling FibroGen stock?

FibroGen's stock was sold by a variety of institutional investors in the last quarter, including Janus Capital Management LLC and Pinnacle Associates Ltd.. Company insiders that have sold FibroGen stock in the last year include Frank H Md Valone, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Rory B Riggs, Thomas B Neff and Thomas F Kearns Jr.

Who bought FibroGen stock? Who is buying FibroGen stock?

FibroGen's stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Renaissance Technologies LLC, Bogle Investment Management L P DE, State Street Corp, A.R.T. Advisors LLC, Oxford Asset Management, Trexquant Investment LP and Russell Investments Group Ltd..

How do I buy FibroGen stock?

Shares of FibroGen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of FibroGen stock cost?

One share of FibroGen stock can currently be purchased for approximately $23.80.

FibroGen (NASDAQ:FGEN) Chart for Wednesday, February, 22, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for FibroGen (NASDAQ:FGEN)

Earnings History Chart

Earnings by Quarter for FibroGen (NASDAQ:FGEN)

Dividend History Chart

Dividend Payments by Quarter for FibroGen (NASDAQ:FGEN)

Last Updated on 2/22/2017 by Staff